Navigation Links
Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales
Date:4/9/2008

) in patients receiving VELCADE. RPLS is a rare, reversible, neurological disorder which can present with seizure, hypertension, headache, lethargy, confusion, blindness, and other visual and neurological disturbances. VELCADE is associated with thrombocytopenia and neutropenia. There have been reports of gastrointestinal and intracerebral hemorrhage in association with VELCADE. Transfusions may be considered. Complete blood counts (CBC) should be frequently monitored during treatment with VELCADE. Rare cases of acute liver failure have been reported in patients receiving multiple concomitant medications and with serious underlying medical conditions.

Integrated Safety Data: Safety data from Phase 2 and 3 studies of single- agent VELCADE 1.3 mg/m2/dose twice weekly for 2 weeks followed by a 10-day rest period in 1163 patients with multiple myeloma (N=1008) and mantle cell lymphoma (N=155) were integrated and tabulated. In these studies, the safety profile of VELCADE was similar in patients with multiple myeloma and mantle cell lymphoma. In the integrated analysis, the most commonly reported adverse events were asthenic conditions (including fatigue, malaise, and weakness) (64%), nausea (55%), diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including peripheral sensory neuropathy and peripheral neuropathy aggravated) (39%), thrombocytopenia and appetite decreased (including anorexia) (each 36%), pyrexia (34%), vomiting (33%), and anemia (29%). Twenty percent (20%) of patients experienced at least 1 episode of greater than or equal to Grade 4 toxicity, most commonly thrombocytopenia (5%) and neutropenia (3%). A total of 50% of patients experienced serious adverse events (SAEs) during the studies. The most commonly reported SAEs included pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, dyspnea and thrombocytopenia (each 3%). Adverse events thought by the investigator to be drug-related and leading to discontinua
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Millennium Announces $200,000 Purchase Order From Greek Distributor
2. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
3. Millennium Over-Delivers on 2007 Goals and Financial Guidance
4. Millennium Biotechnologies Group Reports 40% Sales Increase for Resurgex Product Line in Greek Market
5. Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results
6. Millennium to Receive $40 Million Milestone Payment for Achievement of Sales Threshold for Velcade(R) (Bortezomib) for Injection
7. Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order
8. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
9. Millennium Research Group Offers New Marketrack Service that Tracks European Dental Implant Market
10. Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
11. Millennium to Webcast Third-Quarter 2007 Financial and Operational Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...  Vermillion, Inc. (Nasdaq:   VRML), a bio-analytical solutions ... the Company closed its previously announced private placement ... W. Schuler , Birchview Fund LLC and several ... offering expenses.  The proceeds will be used for ...
(Date:12/24/2014)... 2014 “Preparative & Process Chromatography ... Consumables (Columns, Solvents, Buffers, Valves, Guages, Seals), Accessories, ... - Forecasts to 2019” provides a detailed overview ... market trends, and strategies impacting the preparative and ...
(Date:12/24/2014)... Boston, MA (PRWEB) December 23, 2014 Earlier ... James L. Sherley, director of the Adult Stem Cell Technology ... overlooked and under appreciated unique property of adult tissue stem ... Misunderstood in the Past, Important for the Future,” embodied the ...
(Date:12/24/2014)... 23, 2014 On Friday, December 19, ... Omnibus and Continuing Resolution Appropriations Act of 2015, which ... to receive funding through the Congressionally Directed Medical Research ... The Hydrocephalus Association (HA), working in conjunction with its ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2
... May 2, 2011 Cyberonics, Inc. (Nasdaq: CYBX ... first implant of its AspireSR™ seizure response product on April ... of Professors Paul Boon and Dirk Van Roost and their ... was received by a patient with ictal tachycardia (heart rate ...
... 2011 Today Divine Skin Inc. (OTC Bulletin Board: ... its DS Laboratories line for hair and skin. The company ... the United States. It estimates an average of $300 per ... With well-developed online, luxury, pharmaceutical, and specialty channels, Divine Skin,s ...
... MUNICH, May 2, 2011 Saladax Biomedical, Inc., a ... to achieve the promise of personalized medicine for new ... European commercialization team to expand its European presence. ... and Sales, members of Saladax,s European commercialization team include: ...
Cached Biology Technology:Cyberonics Announces First Implant of AspireSR™ Seizure Response Product in European Trial 2Cyberonics Announces First Implant of AspireSR™ Seizure Response Product in European Trial 3Divine Skin Announces Four Deals for Explosive Distribution Growth 2Divine Skin Announces Four Deals for Explosive Distribution Growth 3Saladax Biomedical, Inc. Announces European Commercialization Team 2Saladax Biomedical, Inc. Announces European Commercialization Team 3
(Date:1/22/2015)... Jan. 21, 2015  Analyst Report Issued by Small Cap IR. ... showed that planet-wide, transactions at merchants on the leading payment ... number of credit, debit, and prepaid cards reached 6.54 billion.  ... of fraudulent card usage in 2012, and credit and debit ...
(Date:12/24/2014)... , Dec. 23, 2014  Since its launch in December 2014, the ... eliminate the pain of trying to remember their usernames and ... fused to their smartphones. To assist people who have struggled ... company that created 1U and focuses on redefining identity, announced ...
(Date:12/19/2014)... 18, 2014 Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) ... North America Perimeter Security Systems Market" report to their ... The North American perimeter security market is estimated to grow ... the U.S. market holds a larger share in this market, ...
Breaking Biology News(10 mins):$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3
... 7, 2008 -- Oncolytics Biotech Inc. (TSX: ONC, ... group led by Dr. Richard Vile of the ... published the results of its work testing the ... reovirus and cyclophosphamide in vivo. The paper, ...
... and Institute of Medicine (IOM) today released SCIENCE, EVOLUTION, ... a comprehensive and up-to-date picture of the current scientific ... classroom. Recent advances in science and medicine, along ... past 150 years, have reinforced evolution,s role as the ...
... which will report on significant advances in all aspects ... genetic diversity and crop improvement. Tropical Plant Biology ... in Springers publishing portfolio. The first issue is ... cover the most rapidly advancing aspects of tropical plant ...
Cached Biology News:Scientific evidence supporting evolution continues to grow 2Scientific evidence supporting evolution continues to grow 3Springer launches Tropical Plant Biology 2
... This special concentrated jetSI 10 nM ... delivery into mouse brain as described in: ... Alfama, C. Giovannangeli, J.-P. Behr, and B.-A. ... gene expression in the mouse brain at ...
... a fluorescein-conjugated jetSI-ENDO (excitation ... 520 nm), the powerful siRNA ... used to determine the transfection ... delivery and trafficking of siRNAs. ...
... Cell and Tissue Staining Kits are intended ... range of histological and cytological specimens. These ... antibodies manufactured by either R&D Systems or ... on the formation of the Avidin-Biotin Complex ...
... wide range of hands-on techniques that are ... all areas of protein chemistry and molecular ... illustrates just how valuable this book will ... introduce the theoretical background of a method ...
Biology Products: